IL-23p19 Antibody Dosing Schedule for Long-Interval Psoriasis Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet need for effective, safe, and affordable biologic treatments for psoriasis, particularly in Chinese patients, as existing IL-23p19 monoclonal antibodies are under-utilized and there is a demand for domestic biological agents with lower treatment costs.
Innovation Solution
A dosing regimen for an IL-23p19 antibody with specific CDR sequences is administered at Weeks 0, 4, and 8, followed by doses every 8 to 20 weeks, preferably every 12 weeks, with a first dose of 200 mg, to improve skin lesions and maintain long-term remission in psoriasis patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing IL-23p19 monoclonal antibodies are used for treatment, then therapeutic efficacy is achieved, but treatment cost is high and accessibility is limited
Solution Approach 1:
The patent creates a domestic copy/version of existing IL-23p19 monoclonal antibodies by identifying and utilizing homologous protein sequences in Chinese patients. This allows development of a treatment that replicates the therapeutic mechanism of imported biologics while being manufactured locally at lower cost, directly addressing the contradiction between efficacy and affordability
Solution Approach 2:
The patent changes the parameter of antigen target specificity by identifying a homologous protein sequence that is specific to Chinese patients rather than using the exact same target as imported antibodies. This parameter change enables the development of a cost-effective domestic alternative that maintains therapeutic efficacy while improving accessibility for Chinese psoriasis patients
2Reliability
If frequent injections are administered to maintain remission, then therapeutic efficacy is maintained, but patient compliance decreases due to physical and psychological burden
Solution Approach 1:
The patent implements a periodic dosing regimen where patients receive initial loading doses followed by maintenance doses at extended intervals (every 8 to 20 weeks). This periodic action pattern maintains therapeutic remission while significantly reducing injection frequency compared to weekly or bi-weekly regimens, thereby improving patient compliance by reducing physical burden and psychological stress associated with frequent injections
3Adaptability or versatility
If biologics are made more accessible to Chinese patients, then health equity improves, but demand for affordable domestic alternatives increases
Solution Approach 1:
The patent develops a cost-effective domestic biologic alternative that can be manufactured at lower cost than imported biologics. By creating an affordable domestic version targeting Chinese patients specifically, the patent makes biologics accessible to a broader population while meeting the demonstrated demand for affordable alternatives, thus improving health equity without requiring expensive imported products
Data Source
AI summary
The present invention relates to a method for preventing or treating psoriasis in a subject, comprising administering an IL-23p19 antibody to the subject, wherein a first dose of the IL-23p19 antibody is administered at Weeks 0, 4, and 8, respectively, followed by administration of a second dose of the IL-23p19 antibody every 8 Weeks to 20 weeks; and wherein the first dose is 200 mg, and the second dose is 50 mg to 250 mg, and preferably 100 mg to 200 mg.